Alteogen Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
1,606
931
1,208
3,587
7,449
Depreciation, Depletion & Amortization
127
166
214
352
423
Other Funds
439
851
109
137
2,246
Funds from Operations
2,171
1,948
1,313
3,372
4,780
Changes in Working Capital
176
738
951
214
433
Net Operating Cash Flow
1,995
1,210
2,264
3,159
4,347
Capital Expenditures
598
85
3,921
2,554
785
Sale of Fixed Assets & Businesses
-
11
-
6
15
Purchase/Sale of Investments
1,670
19,960
314
2,120
609
Net Investing Cash Flow
2,578
20,032
4,235
5,049
319
Issuance/Reduction of Debt, Net
-
187
-
84
-
Net Financing Cash Flow
293
27,289
134
9,394
1,666
Net Change in Cash
287
8,344
1,589
1,308
3,156
Free Cash Flow
1,437
1,177
1,561
4,099
5,053
Net Assets from Acquisitions
310
-
-
520
-
Other Sources
-
3
-
140
-
Change in Capital Stock
293
27,476
134
9,478
1,666
Exchange Rate Effect
2
123
248
122
157
Other Uses
-
-
-
2
159

About Alteogen

View Profile
Address
62 Yuseong-daero 1628beon-gil
Daejeon DE 34054
Korea, Republic Of
Employees -
Website http://www.alteogen.com
Updated 09/14/2018
Alteogen, Inc. engages in the development, manufacture, and sale of biopharmaceuticals and anticancer drugs. Its products include technologies for anti-breast cancer drug and biosimilar, technology consulting, and other services. The company was founded on May 13, 2008 and is headquartered in Daejeon, South Korea.